Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya30870Follow-up study of expression of Bcl-2, Bax, p53 and ACE in CD34+ cells of peripheral blood and bone marrow in acute leukemia patients in the course of induction chemotherapyKhodunovaElena Evgen'evnaHodunova_Lena@mail.ruParovichnikovaElena Nikolaevnaelenap@blood.ruGal'tsevaIrina Vladimirovna-KulikovSergey Mikhaylovich-IsaevValentin Grigor'evich-SavchenkoValeriy Grigor'evich-KhodunovaE EHematological Research Center, Moscow-ParovichnikovaE NHematological Research Center, Moscow-GaltsevaI VHematological Research Center, Moscow-KulikovS MHematological Research Center, Moscow-IsaevV GHematological Research Center, Moscow-SavchenkoV GHematological Research Center, Moscow-Hematological Research Center, Moscow15072011837323710042020Copyright © 2011, Consilium Medicum2011Aim. To determine unbalance in the system of programmed cell death in the cells CD34+ of the bone marrow (BM) and peripheral blood (PB) before and after cytostatic impact in acute leukemia (AL).
Material and methods. Flow cytoflowmetry estimated expression of Bcl-2, Bax, p53 and ACE in the cells CD34+ of BM and PB from 10 AL (4 AML and 6 ALL) patients. PB and BM samples were studied before polychemotherapy (PCT) and in the course of induction treatment: on day +8, +21 (blood only), +36 - 38. Control group consisted of 4 BM donors.
Results. The number of CD34+ cells expressing Bcl-2 in AL patients was 46,5 ± 9,35 % in BM and 39,4 + 10,8 % in PB, in healthy donors - 9 and 32,8 %, respectively. Bax expression in AL patients' cells CD34+ of BM versus this expression in donors was 3 times higher (36,7 ± 8,1 and 14,8%, respectively), of PC - 2 times lower (40,7 ± 6,59 and 75,8%, respectively). Expression of p53 in AL patients was 36,8 ± 9 % in BM and 26 ± 7,4 % in PB, in donors - 28,2 and 65 %, respectively. ACE expression on the cells CD34+ in AL patients in early disease was 62 ± 7,57 % in BM and 48 ± 8,1 % in PB, in donors - 40 and 85 %, respectively. Moreover, there were significant changes in expression of Bcl-2 in BM and Bax, ACE and p53 in PB in the cells CD34+ in AL patients during and after induction PCT.
Conclusion. The above changes evidence for unbalance of pro- and antiapoptosis proteins of regulators in AL patients. PCT changes profile of expression of these proteins, but not to the level of healthy donors.acute leukemiaapoptosisexpression of Bcl-2Bax‡53 and ACEострый лейкозпрограммированная клеточная гибель (апоптоз)экспрессия Всl-2Вахр53 и АПФ[Волкова М. А. (ред.). Клиническая онкогематология: Руководство для врачей. М.: Медицина; 2001.][Савченко В. Г., Паровичникова Е. Н. Лечение острых лейкозов. М. : МЕДпресс-информ; 2004.][Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007; 92(1): 81-94.][Li J., Volkov L. et al. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp. Hematol. 1997; 25: 140-146.][Poeta G. D., Venditti A. et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101(6): 2125-2131.][Marcucci G., Stock W. et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 2005; 23(15): 3404- 3411.][Aksu S., Beyazit Y. et al. Over-expression of angiotensin-converting enzyme (CD143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leukemia and Lymphoma 2006; 47(5): 891-896.][Cavalcanti G. B. Jr., da Cunha Vasconcelos F., Pinto de Faria G. et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B: Clin. Cytom. 2004; 61(1): 1-8.][Antonsson B., Martinou J. C. The Bcl-2 protein family. Exp. Cell Res. 2000; 256(1): 50-57.][Campos L., Rouault J. P., Sabido O. et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091- 3096.][Levine J. L. et al. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.][Ladich H. et al. Molecular cell biology. Scientific American books. New Jork, l995.][Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-1449.][Kaufmann S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989; 49: 5870-5878.][Van Stijn A., Van Der Pol M. A., Kok А. et al. Differences between the CD34+ and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Hematological 2003; 88: 497-508.][Seliger B., Papadileris S., Vogel D. et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur. J. Hematol. 1996; 57: 230-240.][Gump J., Mcgavran L., Wei Q., Hunger S. P. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 2001; 23: 416-425.][Jokubaitis V., Sinka L. et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 2008; 111: 4055- 4063.][Inigo S. D., Lopez-Jorge C. E., Gomez-Casares M. T. et al. Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents. Leukemia Res. 2009; 33: 810-816.][Beyazit Y., Aksu S., Haznedaroglu I. C. et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J. Natl Med. Assoc. 2007; 99: 57-63.][Herr I., Debatin K. M. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98(9): 2603-2614.][Konopleva M., Tari A. M. et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929-3938.][Haznedaroglu I. C., Beyazit Y. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. Renin-Angiotensin-Aldosterone Syst. 2010; 11(4): 205-213.][Aksu S., Beyazit Y., Haznedaroglu I. C. et al. Enhanced expression of the local haematopoietic bone marrow renin-angiotensin system in polycythemia Rubra vera. J. Int. Med. Res. 2005; 33: 661-667.][Srinivas G., Nair N. K., Panicker K. R., Pillai M. R. Mutant p53, Bcl-2/Bax ratios and apoptosis in pediatric acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 2000; 126: 62-67.][Hadir A., Nayera H. et al. The expression of Bcl-2 and Bax Proteins and their clinical relevance in ALL and CLL patients. J. Egypt. Natl. Cancer Inst. 2001; 13(1): 35-42.]